Literature DB >> 8487923

[Continuous intracarotid infusion of mannitol in severe head injury].

H Yokota1, M Nakabayashi, A Fuse, K Mashiko, Y Yamamoto, H Henmi, T Otsuka, S Awaya, S Kobayashi, S Nakazawa.   

Abstract

The clinical significance of continuous intracarotid infusion of a small dose of mannitol (ICI of mannitol) was discussed. Eighteen patients suffering from severe head injury with Glasgow coma scale (GCS) less than 6 were treated by ICI of mannitol for the improvement of raised intracranial pressure (ICP). In all of these 18 cases, conventional venous administration of mannitol could not be carried out, because of the unstable vital signs due to hypovolemic shock such as multiple trauma or disturbance of serum sodium and potassium levels. This method requires that a 20% mannitol solution be directly and continuously administered to the bilateral common carotid artery. The ICP 6 hours after the beginning of ICI of mannitol was significantly lower than the ICP just before the treatment. The total amount of excretion of the sodium and potassium through the urine every hour decreased significantly after this method was used. It was also noticed that this method was very suitable for stabilizing the vital signs in cases which had unstable vital signs such as hypovolemic shock. These findings suggested that ICI of mannitol has an advantage over the conventional venous administration of mannitol in cases which had to have correction of serum electrolyte or which had unstable vital signs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8487923

Source DB:  PubMed          Journal:  No Shinkei Geka        ISSN: 0301-2603


  2 in total

1.  Revisiting intra-arterial drug delivery for treating brain diseases or is it "déjà-vu, all over again"?

Authors:  Shailendra Joshi; Jason A Ellis; Charles W Emala
Journal:  J Neuroanaesth Crit Care       Date:  2014-05

Review 2.  Intracarotid delivery of drugs: the potential and the pitfalls.

Authors:  Shailendra Joshi; Phillip M Meyers; Eugene Ornstein
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.